Atomo Diagnostics Ltd (ASX: AT1) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Atomo Diagnostics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$29.17 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
810.18 million
Earnings per share
-0.008
Dividend per share
N/A
Year To Date Return
2.78%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Atomo Diagnostics Ltd (ASX: AT1)
Latest News
Share Gainers
Guess which ASX healthcare stock just exploded 63% on Federal budget funding news!
Share Gainers
Guess which ASX pharmaceutical stock just rocketed 122%!
Healthcare Shares
3 ASX healthcare shares rocketing 20% to 100% today
Earnings Results
3 ASX healthcare shares punished following full-year results
Earnings Results
Negative result: Atomo Diagnostics (ASX: AT1) shares plunge 18% on half-year earnings
Coronavirus News
Why are ASX COVID test shares climbing today?
Healthcare Shares
Here's why the Atomo (ASX:AT1) share price is rocketing 17% today
Healthcare Shares
Why has the Atomo Diagnostics (ASX: AT1) share price surged 50% since Christmas?
Healthcare Shares
Why is the Atomo Diagnostics (ASX:AT1) share price wobbling on Thursday?
Healthcare Shares
Is AM Diagnostics listed on the ASX?
Share Fallers
Why Afterpay, Atomo, Opthea, & Sealink shares are falling today
Share Market News
Here's why the Atomo (ASX:AT1) share price is crashing 9% today
AT1 ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Atomo Diagnostics Ltd
Atomo Diagnostics Limited is a medical device company. Its Rapid Diagnostic Test devices are used both by healthcare professionals and by consumers to screen for a range of diseases and medical conditions
AT1 Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 13 Jan 2026 | $0.04 | $0.00 | 0.00% | 450,041 | $0.04 | $0.04 | $0.04 |
| 12 Jan 2026 | $0.04 | $0.00 | 0.00% | 54,784 | $0.04 | $0.04 | $0.04 |
| 09 Jan 2026 | $0.04 | $0.00 | 0.00% | 423,573 | $0.04 | $0.04 | $0.04 |
| 08 Jan 2026 | $0.04 | $0.00 | 0.00% | 307,525 | $0.04 | $0.04 | $0.04 |
| 07 Jan 2026 | $0.04 | $0.00 | 0.00% | 2,688,601 | $0.04 | $0.04 | $0.03 |
| 06 Jan 2026 | $0.04 | $0.00 | 0.00% | 324,289 | $0.04 | $0.04 | $0.04 |
| 05 Jan 2026 | $0.04 | $0.00 | 0.00% | 2,130,294 | $0.04 | $0.04 | $0.04 |
| 02 Jan 2026 | $0.04 | $0.00 | 0.00% | 3,094,541 | $0.04 | $0.04 | $0.04 |
| 31 Dec 2025 | $0.04 | $0.00 | 0.00% | 189,201 | $0.04 | $0.04 | $0.04 |
| 30 Dec 2025 | $0.04 | $0.00 | 0.00% | 777,564 | $0.04 | $0.04 | $0.04 |
| 29 Dec 2025 | $0.04 | $0.00 | 0.00% | 939,925 | $0.04 | $0.04 | $0.03 |
| 24 Dec 2025 | $0.04 | $0.00 | 0.00% | 68,731 | $0.04 | $0.04 | $0.04 |
| 23 Dec 2025 | $0.04 | $0.00 | 0.00% | 318,284 | $0.04 | $0.04 | $0.04 |
| 22 Dec 2025 | $0.03 | $0.00 | 0.00% | 512,658 | $0.04 | $0.04 | $0.03 |
| 19 Dec 2025 | $0.04 | $0.00 | 0.00% | 321,851 | $0.04 | $0.04 | $0.04 |
| 18 Dec 2025 | $0.04 | $0.00 | 0.00% | 423,548 | $0.03 | $0.04 | $0.03 |
| 17 Dec 2025 | $0.03 | $0.00 | 0.00% | 1,582,991 | $0.04 | $0.04 | $0.03 |
| 16 Dec 2025 | $0.04 | $0.00 | 0.00% | 334,468 | $0.04 | $0.04 | $0.04 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 12 Dec 2025 | Cheri Walker | Issued | 1,000,000 | $40,000 |
Issue of options.
|
| 12 Dec 2025 | Anthony May | Issued | 700,000 | $28,000 |
Issue of options.
|
| 12 Dec 2025 | Patrick Cook | Issued | 1,400,000 | $56,000 |
Issue of options.
|
| 27 Jun 2025 | Patrick Cook | Issued | 540,541 | $10,000 |
Issue of securities.
|
| 27 Jun 2025 | Patrick Cook | Issued | 540,541 | $8,108 |
Issue of securities.
|
| 27 Jun 2025 | Anthony May | Issued | 540,541 | $8,108 |
Issue of securities.
|
| 27 Jun 2025 | Anthony May | Issued | 540,541 | $10,000 |
Issue of securities.
|
| 27 Jun 2025 | John Kelly | Issued | 1,621,622 | $24,324 |
Issue of securities.
|
| 27 Jun 2025 | John Kelly | Issued | 1,621,622 | $30,000 |
Issue of securities.
|
| 14 Apr 2025 | John Kelly | Expiry | 666,666 | $14,666 |
Options expired.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr John Michael Kelly | FounderChief Executive OfficerManaging Director | Apr 2010 |
Mr Kelly for 25 years has focused on developing and commercialising healthcare products that enhance usability and performance, having started with CR Bard in Europe developing Class III implantable cardiology products. Prior to joining Unilife in 2005, he spent five years at ResMed where he led the New Product Implementation Group and managed the development of the Mirage Swift and Activa mask systems.
|
| Dr Cheri Louise Walker | Non-Executive Director | Nov 2022 |
Dr Walker is an executive with more than twenty-five years of experience working with life science and diagnostic companies. She is currently the Chief Executive Officer of Zeta Corporation. She has previously held senior executive positions at Abcam, Charles River Labs, Qiagen, and Life Technologies, now part of ThermoFisher. She is Chair of Risk Committee.
|
| Mr Anthony May | Non-Executive Director | May 2025 |
Mr May has held various Director roles across international corporations including Hoechst Germany, Microgenics Corporation USA, Fisher Scientific and Thermo Fisher Scientific. With experience across public and private pathology laboratories, as well as sales and management roles in the IVD supply sector, he has built a record in business leadership and strategic growth. He is member of Risk Committee.
|
| Mr Patrick Cook | Non-Executive Director | May 2025 |
Mr Cook has over 35 years of experience as a senior executive in medical devices & point-of-care diagnostics sectors within various multinational, private and listed biotechnology companies. He is member of Risk Committee.
|
| Mr Mathew Leslie Watkins | Company Secretary | Jun 2024 |
-
|
| Chandra Sukumar | Chief Operating Officer |
-
|
|
| Mathew Leslie Watkins | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| GZ Family Holdings Pty Ltd | 89,895,644 | 11.10% |
| Dalraida Holdings Pty Limited | 65,120,000 | 8.04% |
| Global Health Investment Fund | 61,570,716 | 7.60% |
| Wellgrow Investments Pty Ltd | 30,648,649 | 3.78% |
| Gz Super Investments Pty Ltd | 27,027,027 | 3.34% |
| Mr Xiaoyi Lin | 23,760,000 | 2.93% |
| Australia West Holdings Pty | 21,050,000 | 2.60% |
| Australia North Holdings Pty | 19,582,433 | 2.42% |
| Grand Challenges Canada | 11,390,824 | 1.41% |
| Liverbird Pty Ltd | 10,931,653 | 1.35% |
| Boutique Capital Pty Ltd | 10,810,811 | 1.33% |
| I D E Pty Ltd | 9,032,248 | 1.11% |
| John Michael Kelly | 8,991,870 | 1.11% |
| BNP Paribas Nominees Pty Ltd | 8,268,855 | 1.02% |
| Ms Zeyu Shi | 8,134,108 | 1.00% |
| Rue Des Rocs Pty Ltd | 8,000,000 | 0.99% |
| Mark Andrew Smith | 7,790,224 | 0.96% |
| Mr Ian Fredrick Johnson | 7,506,080 | 0.93% |
| Beswick Lynch Super A/C | 7,321,121 | 0.90% |
| Citicorp Nominees Pty Limited | 6,727,298 | 0.83% |
